慢性髓细胞白血病免疫细胞特点与免疫疗法的新进展  

New progress in immune cells characteristics and immunotherapy of chronic myeloid leukemia

作　　者：各力生强 陈舒 王晓冬[1] 代景莹 GELI Shengqiang;CHEN Shu;WANG Xiaodong;DAI Jingying(Department of Hematology,Affiliated Hospital,University of Electronic Science and Technology of China/Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital,Chengdu,Sichuan 610072,China;School of Pharmacy,North Sichuan Medical College,Nanchong,Sichuan 637000,China)

机构地区：[1]电子科技大学附属医院/四川省医学科学院·四川省人民医院血液内科,成都610072 [2]川北医学院药学院,四川南充637000

出　　处：《重庆医学》2024年第20期3173-3178,3183,共7页Chongqing Medical Journal

基　　金：四川省医学科学院·四川省人民医院临床研究与转化基金项目(2020LZ0)。

摘　　要：慢性髓细胞白血病(CML)是一种以出现Ph染色体并形成BCR-ABL融合基因为特征的血液系统恶性肿瘤。随着酪氨酸激酶抑制剂的出现,CML的疗效和生存期得到了明显改善。然而,仍有部分患者不可避免地发生疾病进展、复发。CML患者机体自身的抗肿瘤免疫可发挥监视、识别及清除白血病细胞的作用,与疾病发生、发展、疗效及预后密切相关。而自然杀伤(NK)细胞、T细胞、树突状细胞(DC)、调节性T细胞(Treg)、髓源性抑制细胞(MDSCs)等免疫细胞在CML患者抗肿瘤免疫中发挥关键作用。由此,该文对CML免疫细胞的特点、机体自身抗肿瘤免疫状态与疗效相关性和目前CML免疫疗法的进展进行综述。Chronic myeloid leukemia(CML)is a hematological system malignant tumor characterized by the appearance of Ph chromosomes and the formation of BCR-ABL fusion gene.With the emergence of tyrosine kinase inhibitors,the efficacy and survival of CML have been improved significantly.However,there are still some patients with inevitable disease progression and recurrence.In CML patients,the body’s own anti-tumor immunity can play a role in monitoring,recognizing and eliminating the leukemia cells,which is closely correlated wit h the occurrence,development,curative efficacy and prognosis of the disease.The immune cells such as natural killer(NK)cells,T cells,dendritic cells,Treg and MDSC play a key role in anti-tumor immunity.Therefore,this article reviews the characteristics of CML immune cells,correlation between the body’s own anti-tumor immune status and therapeutic effect,and the recent progress of CML immunotherapy.

关 键 词：慢性髓细胞白血病 酪氨酸激酶抑制剂 自然杀伤细胞 T细胞 树突状细胞 髓源性抑制细胞 调节性T细胞 综述 

分 类 号：R733.7[医药卫生—肿瘤]